background
rapid
reliabl
diagnosi
respiratori
viral
infect
rvi
lung
transplant
recipi
essenti
direct
therapi
acut
graft
dysfunct
identifi
epidem
trend
tradit
techniqu
serolog
viral
cultur
limit
lack
antibodi
respons
delay
diagnosi
examin
clinic
util
indirect
fluoresc
antibodi
ifa
test
adult
lung
transplant
patient
suspect
rvi
compar
serolog
cultur
nasopharyng
throat
swab
nt
obtain
sampl
epitheli
cell
follow
applic
monoclon
antibodi
respiratori
syncyti
viru
adenoviru
parainfluenza
influenza
b
bartel
respiratori
viral
detect
kit
use
ifa
result
avail
within
hour
nine
patient
test
posit
rvi
influenza
n
influenza
b
n
detect
sensit
ifa
higher
cell
cultur
intens
support
therapi
infect
selflimit
bronchiol
obliteran
syndrom
bo
grade
patient
howev
patient
bo
grade
manifest
acut
exacerb
airflow
obstruct
prove
irrevers
lung
transplant
patient
flulik
symptom
proceed
ifa
test
nt
swab
specimen
earli
diagnosi
sampl
collect
within
day
symptom
onset
high
sensit
compar
serolog
viral
cultur
techniqu
cotton
swab
moisten
physiolog
salin
insert
nostril
gentli
rotat
absorb
secret
posterior
nasopharyng
area
second
swab
use
vigor
rub
posterior
oropharynx
swab
place
hopkin
et
al
respi
ratori
viral
infect
rvi
common
immunocompromis
patient
associ
signific
morbid
mortal
approach
lung
transplant
recipi
uniqu
predisposit
infect
diminish
cough
reflex
abnorm
lymphat
drainag
impair
mucociliari
clearanc
preexist
airway
damag
oblit
bronchiol
clinic
manifest
may
includ
acut
selflimit
pharyng
bronchiol
viral
pneumonia
respiratori
failur
secondari
bacteri
infect
well
recogn
along
predisposit
acut
allograft
reject
bronchiol
obliteran
syndrom
bo
local
immun
upregul
earli
diagnosi
essenti
direct
therapi
acut
graft
dysfunct
identifi
epidem
trend
transplant
commun
prevent
nosocomi
acquisit
infect
histor
laboratori
techniqu
util
diagnosi
rvi
serolog
viral
cultur
direct
antigen
detect
serolog
confirm
infect
use
acut
convalesc
serum
signific
drawback
transplant
recipi
includ
delay
diagnosi
lack
antibodi
respons
possibl
crossreact
tradit
viral
cultur
remain
gold
standard
diagnosi
although
requir
day
incub
achiev
maxim
sensit
isol
embryon
hen
egg
lung
carcinoma
primari
monkey
kidney
madindarbi
canin
kidney
mdck
cell
line
constitut
classic
method
diagnosi
respiratori
virus
detect
viral
antigen
within
clinic
sampl
use
direct
indirect
fluoresc
antibodi
dfa
ifa
techniqu
propos
altern
achiev
rapid
diagnosi
immunocompromis
patient
palmer
colleagu
describ
case
rvi
lung
transplant
recipi
diagnos
dfa
perform
bronchoalveolar
lavag
bal
fluid
howev
exfoli
epitheli
cell
deriv
upper
respiratori
tract
may
practic
less
invas
sourc
diagnost
materi
patient
success
examin
influenza
viru
nasal
smear
fluoresceinlabel
antibodi
first
describ
year
ago
although
nasopharyng
aspir
wide
recogn
provid
suffici
cell
fluoresc
antibodi
screen
number
inher
problem
includ
inconveni
collect
propens
induc
trauma
patient
fragil
mucosa
scant
nasal
secret
nasopharyng
throat
nt
swab
may
ideal
specimen
provid
cellular
materi
howev
applic
viral
diagnosi
transplant
recipi
remain
poorli
describ
studi
prospect
analyz
clinic
util
ifa
test
nt
swab
specimen
diagnosi
rvi
compar
serolog
cell
cultur
adult
lung
transplant
recipi
also
character
local
epidemiolog
clinic
manifest
potenti
longterm
complic
rvi
transplant
popul
studi
period
commenc
juli
adult
lung
transplant
patient
present
flulik
symptom
st
vincent
hospit
sydney
underw
nt
swab
ifa
test
viral
cultur
use
bartel
respiratori
viral
detect
kit
cost
us
flulik
symptom
defin
combin
sore
throat
nasal
irrit
lowgrad
fever
myalgia
arthralgia
without
lower
respiratori
tract
lrt
symptom
cough
dyspnea
wheez
follow
nt
swab
blood
sampl
sent
acut
viral
serolog
influenza
b
adenoviru
use
complement
fixat
assay
cytomegaloviru
polymeras
chain
reaction
cmv
pcr
analysi
full
blood
count
biochemistri
immunosuppress
level
detail
pulmonari
function
test
chest
radiograph
measur
oxygen
satur
also
perform
select
patient
signific
lrt
symptom
andor
radiograph
infiltr
proceed
earli
fiberopt
bronchoscopi
transbronchi
lung
biopsi
tbb
bal
sampl
process
viral
studi
ifa
test
result
avail
within
hour
collect
convalesc
serolog
respiratori
virus
collect
week
clinic
present
lung
function
chart
month
postinfect
baselin
forc
expiratori
volum
second
fev
defin
averag
measur
record
month
preced
clinic
present
separ
least
week
diagnosi
rvi
requir
posit
viral
cultur
ifa
test
demonstr
rise
serum
antibodi
titer
studi
particip
receiv
similar
immunosuppress
therapi
earli
posttransplant
consist
oral
cyclosporin
azathioprin
prednisolon
mainten
dose
mgkg
acut
reject
treat
intraven
methylprednisolon
mgkg
per
day
day
gener
follow
oral
taper
commenc
mgkg
patient
switch
cyclosporin
tacrolimu
mgkg
recurr
persist
reject
ml
viral
transport
medium
transport
immedi
outsid
refer
laboratori
km
institut
upon
arriv
liquid
medium
swab
mix
togeth
centrifug
provid
cellular
supernat
specimen
least
epitheli
cell
per
field
light
microscopi
consid
adequ
viral
detect
half
cell
remov
pasteur
pipett
place
onto
slide
ifa
test
consist
two
immunolog
reagent
first
l
antivir
mous
monoclon
antibodi
adenoviru
respiratori
syncyti
viru
rsv
influenza
b
parainfluenza
inocul
well
l
nonimmun
mous
antibodi
ad
final
well
neg
control
specimen
incub
humid
chamber
minut
wash
phosphatebuff
salin
antimous
immunoglobulin
conjug
fluoresceinisothiocyan
ad
wash
remov
unattach
reagent
antigen
well
examin
magnif
nonimmun
mous
well
examin
first
detect
nonspecif
background
immunofluoresc
cell
infect
viru
display
applegreen
fluoresc
cytoplasm
andor
nuclear
uniform
punctat
distribut
remain
cell
supernat
nt
swab
process
cultur
isol
incub
mdck
cell
cell
observ
daili
cytopath
chang
vacuol
stain
respiratori
viru
incub
outlin
earlier
viral
infect
observ
subject
test
case
influenza
infect
influenza
influenza
b
case
adenoviru
rsv
parainfluenza
occur
evalu
period
presum
diagnos
patient
neg
diagnost
test
n
common
respiratori
viral
pathogen
routin
test
rhinoviru
coronaviru
figur
outlin
distribut
infect
vs
time
posttransplant
evalu
month
august
septemb
case
rvi
detect
month
juli
infect
peak
septemb
correspond
earli
spring
australia
observ
predomin
patient
year
posttransplant
tabl
highlight
method
diagnosi
influenza
patient
accord
symptom
durat
present
seven
influenza
patient
test
within
week
clinic
symptom
ifa
compon
diagnost
test
detect
case
sensit
case
miss
ifa
subsequ
detect
viral
cultur
assay
howev
ifaposit
case
cultur
neg
give
sensit
cultur
patient
subgroup
two
patient
delay
clinic
present
beyond
week
neg
nt
swab
diagnos
basi
serolog
convers
therefor
overal
sensit
ifa
test
vs
viral
cultur
serolog
referr
popul
transplant
subject
commun
base
case
nosocomi
acquisit
studi
period
nt
swab
process
ifa
viral
cultur
specimen
reject
inadequ
cell
number
characterist
lung
transplant
recipi
influenza
infect
shown
tabl
ii
patient
rang
age
year
diagnos
day
posttranspl
mean
day
prior
influenza
infect
major
patient
baselin
lung
function
consist
bo
grade
n
patient
receiv
augment
immunosuppress
antireject
treatment
diagnosi
subject
except
experienc
signific
morbid
infect
lrt
symptom
acut
declin
lung
function
andor
requir
hospit
admiss
bacteri
coinfect
document
sputum
bronchoalveolar
lavag
bal
sampl
patient
receiv
intraven
antibiot
patient
also
receiv
antiinflammatori
dose
oral
prednisolon
commenc
mgkg
taper
mgday
usual
mainten
dose
howev
steroid
puls
given
patient
symptom
limit
upper
respiratori
tract
normal
graft
function
patient
signific
methicillinresist
staphylococcu
aureu
mrsa
infect
antivir
therapi
amantadin
select
neuraminidas
inhibitor
administ
studi
particip
tbb
perform
patient
radiolog
infiltr
reveal
intens
airwaycent
inflamm
neutrophil
case
one
procedur
confirm
moder
acut
allograft
reject
associ
lymphocyt
bronchiol
grade
shown
tabl
iii
influenza
subject
similar
age
gender
transplant
type
postop
day
patient
respiratori
viru
isol
n
particip
group
mainten
immunosuppress
agent
time
clinic
infect
howev
declin
fev
influenza
subject
significantli
greater
compar
noninfluenza
group
p
mannwhitney
utest
five
influenza
patient
develop
new
chest
radiograph
infiltr
compar
none
noninfluenza
group
although
presenc
hypoxemia
leukocytosi
show
similar
distribut
among
group
fever
particularli
characterist
influenza
infect
noninfluenza
patient
experienc
less
sever
clinic
present
requir
hospit
case
augment
oral
steroid
infrequ
interestingli
studi
particip
except
receiv
singledos
influenza
vaccin
month
prior
evalu
period
outcom
favor
patient
case
progress
respiratori
failur
requir
intub
assist
ventil
figur
demonstr
lung
function
studi
particip
bo
grade
baselin
month
clinic
present
bo
grade
influenza
noninfluenza
subject
experienc
acut
revers
declin
fev
return
baselin
mean
week
clinic
present
howev
influenza
patient
bo
grade
fail
return
baselin
suffer
progress
loss
lung
function
thereaft
contrast
bo
grade
subject
noninfluenza
group
occur
despit
bo
grade
subject
receiv
intraven
cefepim
tobramycin
concurr
pseudomona
chest
infect
oral
puls
steroid
inpati
stay
although
noninfluenza
subject
hypoxem
present
declin
lung
function
less
sever
neither
new
radiograph
infiltr
one
noninfluenza
bo
grade
patient
concurr
aspergillu
infect
necessit
subject
influenza
year
lavag
sampl
taken
lung
transplant
patient
retrospect
review
incorpor
surveil
diagnost
biopsi
protocol
bal
fluid
diagnost
specimen
contrast
significantli
prospect
evalu
perform
immunocompromis
patient
hematolog
malign
bone
marrow
transplant
bmt
use
upper
respiratori
tract
sampl
techniqu
ljungman
et
al
report
patient
respiratori
viru
detect
nasal
wash
studi
period
vast
major
patient
symptomat
larg
prospect
studi
postbmt
compar
isol
site
confirm
influenza
infect
show
lavag
sampl
vs
nasal
washthroat
swab
specimen
dfaor
cultureposit
viru
report
case
influenza
infect
period
lung
transplant
recipi
flulik
symptom
transplant
commun
sever
addit
factor
may
explain
higher
preval
infect
season
geograph
variat
along
heighten
effort
diagnos
infect
nonetheless
incid
influenza
infect
adult
lung
transplant
recipi
like
consider
greater
report
date
specif
applic
diagnost
test
obtain
upper
respiratori
tract
tradit
cell
cultur
techniqu
remain
gold
standard
respiratori
viral
diagnosi
howev
sensit
viral
cultur
compar
rapid
diagnost
method
well
describ
lung
transplant
recipi
seri
ifa
test
sampl
superior
sensit
vs
cell
cultur
vs
garantzioti
et
al
report
similar
find
lavag
fluid
small
seri
case
influenza
pneumonia
lung
transplant
recipi
lower
rate
posit
viral
cultur
may
reflect
vitro
viral
instabl
suboptim
specimen
handl
although
sampl
sent
outsid
refer
laboratori
inocul
cell
cultur
ifa
stain
achiev
within
hour
sampl
frozen
transport
may
otherwis
promot
cellular
degrad
reduc
viral
stabil
exclud
patient
clinic
present
beyond
week
sensit
ifa
improv
significantli
possibl
viral
isol
enhanc
specimen
collect
within
day
clinic
onset
high
sensit
ifa
test
seri
support
use
nasopharyng
throat
swab
diagnost
specimen
collect
method
well
toler
patient
specimen
discard
recollect
inadequ
cell
number
nasopharyng
aspir
andor
wash
propos
altern
method
collect
larger
number
exfoli
epitheli
cell
howev
techniqu
potenti
invas
inconveni
collect
compar
nt
swab
addit
nasal
secret
minim
mucosa
particularli
fragil
common
influenza
nt
swab
may
inflict
less
local
trauma
stipul
cellular
appli
studi
would
like
reduc
dispar
yield
variou
upper
airway
sampl
techniqu
influenza
produc
signific
clinic
infect
lung
transplant
patient
necessit
hospit
singl
bed
isol
support
care
major
affect
individu
radiograph
anomali
predict
sever
graft
dysfunct
develop
respiratori
failur
patient
requir
ventilatori
support
die
result
acut
infect
knowledg
antivir
agent
proven
efficaci
influenza
infect
transplant
recipi
inhal
zanamivir
oral
oseltamivir
select
inhibitor
neuraminidas
glycoprotein
essenti
replic
influenza
b
virus
studi
immunocompet
volunt
shown
agent
reduc
durat
diseas
day
sever
ill
secondari
complic
compar
placebo
initi
within
hour
symptom
onset
ifa
test
may
facilit
broader
applic
novel
agent
transplant
recipi
rapid
confirm
infect
although
describ
influenza
gener
selflimit
acut
set
strategi
reduc
morbid
may
prove
costeffect
research
need
defin
potenti
subgroup
transplant
recipi
may
benefit
earli
introduct
neuraminidas
inhibitor
serolog
low
sensit
diagnos
recent
influenza
infect
confirm
percent
case
seri
poor
respons
similar
achiev
influenza
vaccin
patient
thorac
organ
transplant
protect
antibodi
level
seen
recipi
major
public
health
measur
prevent
influenza
infect
remain
use
inactiv
vaccin
administ
autumn
year
nonetheless
vaccin
lung
transplant
recipi
yearli
singledos
influenza
vaccin
may
afford
minim
protect
viral
replic
infect
except
patient
vaccin
influenza
month
prior
evalu
period
add
controversi
debat
regard
need
booster
vaccin
serolog
confirm
antibodi
respons
howev
feasibl
vaccin
patient
group
protect
individu
sever
clinic
manifest
induc
low
serum
level
protect
antibodi
specif
assay
measur
antibodi
vaccin
constitu
becom
wide
avail
continu
recommend
least
singledos
influenza
vaccin
retrospect
clinic
review
support
associ
rvi
develop
bo
season
cluster
onset
bo
suggest
infecti
trigger
respiratori
virus
may
play
etiolog
role
oblit
bronchiol
recent
describ
shortli
influenza
pneumonia
pediatr
adult
lung
transplant
recipi
experiment
intratrach
instil
parainfluenza
rat
lung
allograft
induc
typic
lesion
oblit
bronchiol
within
day
histolog
section
palmer
describ
patient
develop
bo
immedi
follow
rvi
sever
month
infect
studi
patient
experienc
similar
revers
declin
lung
function
progress
bo
worsen
bo
grade
followup
howev
bo
grade
patient
influenza
fail
return
baselin
experienc
ongo
loss
thereaft
suggest
patient
sever
preexist
bronchiolar
epitheli
damag
limit
repertoir
defens
mechan
respiratori
virus
compon
patholog
influenza
caus
recruit
cell
site
infect
perhap
use
oral
prednisolon
treatment
regimen
lower
bo
grade
protect
patient
initi
amplif
chronic
reject
process
mechan
action
steroid
blockad
may
includ
downregul
lymphocyt
alloreact
minim
subepitheli
inflammatori
reaction
addit
acut
reject
infrequ
associ
influenza
infect
biopsyproven
grade
reject
day
hospit
conclus
influenza
lung
transplant
recipi
probabl
far
preval
previous
report
although
studi
popul
rel
small
believ
ifa
test
nt
swab
lowcost
less
invas
test
high
sensit
diagnosi
infect
routin
viral
cultur
nt
swab
may
necessari
initi
posit
ifa
given
lower
sensit
experi
earli
diagnosi
institut
intens
support
treatment
infect
gener
selflimit
show
infrequ
associ
acut
reject
except
bo
grade
patient
found
associ
subsequ
develop
bo
month
followup
although
recommend
annual
influenza
vaccin
singledos
protocol
may
provid
minim
protect
diseas
